



NEURALY

Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson's Disease

This study is to determine the efficacy, safety, and tolerability of 36 weeks of treatment with 2 dosages of NLY01, relative to placebo in treating Parkinson's disease. The study will roughly last 45 to 54 weeks and will include 1 or more screening visits, 7 clinic visits, 5 telephone visits, and 2 follow-up visits. The study drug will either be NLY101 or placebo. Subjects will be taught to inject the drug under his/her skin once a week. Subjects will be compensated for their participation

ARE YOU ELIGIBLE?

- Must be least 30 years of age and no more than 80 years of age (inclusive) at screening.
- Must have early stage of Parkinson's disease with no movement symptoms of Parkinson's disease that appeared more than 5 years ago.
- Able and willing to comply with scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study.
- If you are capable of becoming pregnant or fathering a child, you will need to use a highly effective form of birth control during the study and for 30 days after the last dose of study drug.
- Please inquire for more about eligibility criteria if interested.

INTERESTED?

Contact Raymond James at 617-638-7745, or rcjames@bu.edu.